ina and has market-leading R&D capabilities, focusing on innovative and first-to-market generic drugs. Sihuan Pharmaceutical has been listed on the Main Board of the Hong Kong Stock Exchange since October 2010. Key Contact NeuroVive Pharmaceutical: Mikael Bronnegard Email: [email protected] Phone No: +4